Bob Kramer: I think that’s our expectation of what will happen, Chris, but I am not going to speculate on what actions or preferences the FDA would like. But that’s our expectation is, it would be OTC only after some transition period later this year.
Unidentified Analyst: Okay. On the travel health sale, to an extent you can give us some color, given that all the financials were now disclosed. What kind of valuation you received on that sale or divestment?
Bob Kramer: So as we included in our press release when we announced the signing of the transaction, the total consideration that’s been agreed with the other party is $380 million of value, Chris, $270 million of which is up upfront payment with another $110 million being potentially in the form of either development-based milestones for the chikungunya product as it goes through its development stages, as well as some milestone payments based on future sales of both the Vaxchora and the Vivotif product. So $270 million upfront, plus another $110 million potentially in development and sales-based milestones down the road.
Unidentified Analyst: I am sorry I meant of any valuation metrics your can provide in sales or EBITDA or any color?
Bob Kramer: Yeah. We obviously went through the normal and traditional valuation metrics based on multiples of revenue and EBITDA and looked at kind of competing products in the market, Chris. We think that the — where we landed with Bavarian Nordic represents fair value. But more importantly, it’s — I think Bavarian Nordic is a great partner to transition these assets to — they are committed to this space. They have experience in other products in this space and will serve well the very patients and customers who need these products going forward.
Unidentified Analyst: Okay. And finally, to an extent you can provide us a little bit more color on going from like $306 million revenues fourth quarter to around $130 million to $150 million, if you can kind of provide a little bit more color, what are the pushes and pulls, that will be helpful.
Bob Kramer: Yeah. I think historically, Chris, our business has had revenues that are lower in the first quarter and certainly the first half of the year versus the second half of the year. I think if you go back and look quarter-by-quarter and first half versus second half, historically, roughly 40% of our revenues have occurred in the first half of the year with 60 — sometimes 60%-plus in the second half. So this is not out of the ordinary for us and it’s really the nature of our deliveries for the medical countermeasure products that we have under contract with the U.S. Government. I don’t know if, Rich, if you want to add anything to that?
Rich Lindahl: No. I think that’s right. It’s really just is an inherently lumpy nature to those deliveries and it’s very common that the fourth quarter ends up being our strongest quarter of the year and the first quarter being our — being sequentially lower and that’s a similar trend we are expecting this year.
Unidentified Analyst: Perfect. Thank you.
Operator: Thank you. And one moment for our next question. We have a follow-up question from the line of Boris Peaker with Cowen. Your line is open. Please go ahead.
Boris Peaker: Hi. Well, thanks for taking my follow-up. I guess one question that is in mind of a lot of investors in terms of your debt maturity. Can you talk about maybe the time line or what we should be expecting in terms of your strategy or communication with the debtors in terms of this process?
Bob Kramer: Sure, Boris. Thanks. Rich, do you want to take that one?
